=Arbutus Biopharma (ABUS) reported earnings on Thur 2 Nov 2017 (a/h)

Net Loss
For Q3 2017, the net loss was $11.6 million ($0.21 basic and diluted loss per common share) as compared to a net loss of $19.6 million ($0.37 basic and diluted loss per common share) for Q3 2016. The net loss for the nine-months ended September 30, 2017 was $48.5 million ($0.89 basic and diluted loss per common share) as compared to a net loss of $165.5 million ($3.15 basic and diluted loss per common share) for the nine-months ended September 30, 2016.

Revenue
Revenue was $6.9 million in Q3 2017 as compared to $0.8 million in Q3 2016.
In March 2017, Arbutus signed a License Agreement with Alexion that granted them exclusive use of the Company's proprietary lipid nanoparticle (LNP) technology in one of Alexion's rare disease programs. Licensing fee revenue recognized in Q3 2017 relates to the non-refundable upfront payment of $7.5 million for the use of Arbutus' technology. In addition, Arbutus recognized revenue for services provided to Alexion related to technology development, manufacturing and regulatory support for the advancement of Alexion's mRNA product candidate. In July 2017, the Company received notice of termination from Alexion for the LNP license agreement. Therefore, Arbutus recorded the remaining deferred revenue for the non-refundable upfront payment as well as any revenue for any work done related to closeout procedures in Q3 2017.
Revenue in Q3 2016 related primarily to the Dicerna license and collaboration that was terminated in November 2016.
In addition, Arbutus has ongoing license agreements with Alnylam and Spectrum, under which Arbutus is eligible to receive commercial royalties.

Tekmira Pharmaceuticals (TKMR) changes its name to Arbutus Biopharma (ABUS)

Tekmira Pharmaceuticals (TKMR) is shifting focus after years of up-and-down development, planning to change its name to Arbutus Biopharma (ABUS) and  focus on drugs to treat hepatitis B.

  

• The Canadian biotech will do business as Arbutus Biopharma come Aug. 6, 2015.
• Headquarters: Burnaby, Canada
• Founded: 2007

Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola.  Tekmira was developing it under a $140 million US Department of Defense contract.

 While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.

Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.

The next month, Tekmira changed its name to Arbutus Biopharma.